A prospective study of serum adiponectin and regression of metabolic syndrome: The ARIRANG study

Kim, Jang Young; Yadav, Dhananjay; Ahn, Song Vogue; Koh, Sang Baek

doi:10.1016/j.bbrc.2015.09.007

Cited by 11 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Close hypoadiponectinemia–MetS association indicates impaired adipocyte function might significantly influence systemic insulin resistance (Stern et al, 2007 ; Klöting and Blüher, 2014 ). Revese effect of ADPQ on insulin resistance in animal and epidemiological studies (Yamauchi et al, 2001 ; Kim et al, 2015 ). was also indicative of its clinical implication and potential therapeutic value on MetS.…”

Section: Discussionmentioning

confidence: 99%

Meta-Analysis of Adiponectin as a Biomarker for the Detection of Metabolic Syndrome

et al. 2018

View full text Add to dashboard Cite

Previous studies revealed the potential significance of circulating adiponectin levels with respect to the diagnosis and prediction of metabolic syndrome, but uncertainty has been noted across different cohorts. Systematic evaluation was performed for diagnostic accuracy and predictivity of adiponectin variation for metabolic syndrome in enrolled studies including 1,248 and 6,020 subjects, respectively. Adiponectin can identify metabolic syndrome with moderate accuracy (area under the curve = 0.81, 95% CI: 0.77–0.84). Heterogeneity analysis revealed that an increasing index of insulin resistance was independently associated with improving the performance of adiponectin upon metabolic syndrome diagnosis (ratio of diagnostic odds ratio = 3.89, 95% CI: 1.13–13.9). In addition, reductions in adiponectin were associated with increasing metabolic syndrome incidence in a linear dose-response manner. The risk of hypoadiponectinemia with metabolic syndrome was especially increased in men (P < 0.05). Further Mendelian randomization analysis identified that the amplified risk could be attributed to increased susceptibility (up to 7%) to insulin resistance compared with women. In conclusion, adiponectin measurement might have potential benefits in the detection of metabolic syndrome. Factors that affect insulin resistance should be considered for adjustment in future assessments.

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-Analysis of Adiponectin as a Biomarker for the Detection of Metabolic Syndrome

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A large body of researches have demonstrated that low adiponectin levels may associate with risks and the severity of MS [12][13][14]. By contrast, increased adiponectin levels have been proven as an independent protector for the development and regression of MS in several prospective studies [15,16].…”

Section: Introductionmentioning

confidence: 99%

Fetuin-a to adiponectin ratio is a sensitive indicator for evaluating metabolic syndrome in the elderly

et al. 2020

View full text Add to dashboard Cite

Background: Fetuin-A and adiponectin present significant associations, supported by recent evidence, with metabolic syndrome (MS) featuring hyperglycemia, central obesity and insulin resistance as the main components, but their biological functions are opposite. The aim of this study was to verify whether fetuin-A/adiponectin ratio (F/A ratio) is a more sensitive indicator for evaluation of MS than either fetuin-A or adiponectin. Methods: In this cross-sectional study, 465 elderly subjects were selected from the physical examination database. Serum levels of fetuin-A and adiponectin were measured using an enzyme-linked immunosorbent assay (ELISA) method. Spearman's rank correlation coefficient, linear regression and logistic regression analysis were adopted to estimate the correlations of fetuin-A, adiponectin and F/A ratio with MS and its components, and receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive values of the aforesaid indices. Results: Compared with fetuin-A or adiponectin, F/A ratio was significantly associated with all the components of MS, and this correlation was significant even after adjusting potential confounding factors (P < 0.05). Logistic regression analysis indicated that F/A ratio presented a stronger correlation with incident MS (adjusted OR: 1.466; 95% CI: 1.189-1.808) than fetuin-A (adjusted OR: 1.100; 95% CI: 1.020-1.186) and adiponectin (adjusted OR: 0.760; 95% CI: 0.664-0.871) alone. ROC analysis revealed that F/A ratio achieved a larger area under curve (AUC) than fetuin-A and adiponectin, with their AUC values of 0.755, 0.709 and 0.708, respectively. Conclusion: F/A ratio is a more sensitive index for evaluating MS than either fetuin-A or adiponectin in the elderly.

show abstract

“…[20–22]. Accordingly, the level of adiponectin is associated with obesity-related disorders and metabolic risk factors [23–26]. Adiponectin levels are inversely correlated with visceral obesity; therefore, high levels of adiponectin are negative correlated with obesity whereas low adiponectin levels exhibit a positive correlation 9 .…”

Section: Introductionmentioning

confidence: 99%

Visceral Fat Area and Serum Adiponectin Level Predict the Development of Metabolic Syndrome in a Community-Based Asymptomatic Population

et al. 2017

View full text Add to dashboard Cite

BackgroundAlthough it has been demonstrated that visceral adipose tissue content and serum levels of adiponectin are associated with metabolic syndrome, their predictive potential for the development of metabolic syndrome remains to be elucidated.MethodsWe studied 1,130 participants of the Seoul Metabolic Syndrome cohort. A total of 337 subjects without metabolic syndrome underwent the follow-up evaluation and finally analyzed. Visceral fat area (VFA) was measured using dual bioelectrical impedance analysis. We compared the 1-year incidence rate of metabolic syndrome among four different groups: Group 1 (high adiponectin level and low VFA), Group 2 (low adiponectin level and low VFA), Group 3 (high adiponectin level and high VFA) and Group 4 (low adiponectin level and high VFA).ResultsMedian follow-up duration was 17 months. Cut-off points of adiponectin level and VFA for metabolic syndrome were 7.34 ng/ml and 84 cm2 for men, and 12.55 and 58 cm2 ng/ml for women, respectively. The incidence of metabolic syndrome was the highest in Group 4 (Group 1; 16.47%, Group 2; 22.08%, Group 3; 25%, and Group 4; 46.15%, p<0.001). Adjusted logistic regression analyses for metabolic syndrome prediction demonstrated that Group 4 exhibited the highest odds ratio compared with Group 1 (4.918 [2.05–11.795]), which was predominantly affected by waist circumference and serum triglyceride levels. Notably, triglyceride/high-density lipoprotein cholesterol (TG/HDL) ratio was significantly higher in Group 4 (p = 0.017).ConclusionIncidence rate of metabolic syndrome was the highest in subjects with low serum adiponectin levels and high visceral fat area. Higher TG/HDL ratio in these subjects suggested insulin resistance may contribute to the development of metabolic syndrome.

show abstract

A prospective study of serum adiponectin and regression of metabolic syndrome: The ARIRANG study

Cited by 11 publications

References 32 publications

Meta-Analysis of Adiponectin as a Biomarker for the Detection of Metabolic Syndrome

Meta-Analysis of Adiponectin as a Biomarker for the Detection of Metabolic Syndrome

Fetuin-a to adiponectin ratio is a sensitive indicator for evaluating metabolic syndrome in the elderly

Visceral Fat Area and Serum Adiponectin Level Predict the Development of Metabolic Syndrome in a Community-Based Asymptomatic Population

Contact Info

Product

Resources

About